Fellow ALC Shareholders - I have great news!
On 13-Dec (US Time), a major FDA reform bill became law!
http://www.natlawreview.com/article/major-fda-reform-bill-becomes-law-medical-device-overview
This has enormous implications for ALC specifically under "Section 3060 - Clarifying Medical Software Regulation" in the bill, of which the highlights are in the article.
Our MIYA suite of products
NO LONGER REQUIRES FDA CLASS II APPROVAL
This makes the entry in to the most lucrative market in the world that much easier! For those of you who are avid healthcare / healthtech investors, you will appreciate the implications of this & how large they are.
The passing of this law also has huge implications (positive) for RAP & I've posted something to this effect on their forum. I do note that for RAP, they had a huge volume & price 'up day' on 14-Dec which was the first opportunity for the Aussie market to trade on this news.
This tells me 2 things:
1 - US Insto investors are all over RAP
2 - US Insto investors are NOT across ALC & hence there is a huge opportunity for this re-rate to continue given Brian Leedman is a common director to both companies & will no doubt be pitching ALC's benefits to those US Instos who are invested in to RAP.
I am super excited about this regulatory change & the 'impact' has not been priced in to this stock at all !!!
